Plasma Neuroendocrine Markers in Patients with Benign Prostatic Hyperplasia and Prostatic Carcinoma
- 1 April 1996
- journal article
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 155 (4) , 1340-1343
- https://doi.org/10.1016/s0022-5347(01)66261-x
Abstract
No abstract availableThis publication has 16 references indexed in Scilit:
- Neuroendocrine differentiation in prostatic adenocarcinoma and its relationship to tumor progressionCancer, 1994
- Effect of somatostatin analog RC‐160 and bombesin/gastrin releasing peptide antagonist RC‐3095 on growth of PC‐3 human prostate‐cancer xenografts in nude miceInternational Journal of Cancer, 1993
- Neuroendocrine differentiation in human prostatic carcinomaHuman Pathology, 1992
- The inhibition of the paracrine progression of prostate cancer as an approach to early therapy of prostatic carcinomaJournal of Cellular Biochemistry, 1992
- Prostatic Carcinoma: Histological and Immunohistological Factors Affecting PrognosisBritish Journal of Urology, 1990
- Bombesin stimulates growth of human prostatic cancer cellsin vitroCancer, 1990
- Immunoreactive Somatostatin in Male Reproductive System in Humans*Journal of Clinical Endocrinology & Metabolism, 1989
- Tumour pathology of the neuron-paraneuron system and its evolutionary background, with special attention to neuro-endocrine differentiation in prostate and mammary carcinomas.Archives of Histology and Cytology, 1989
- Neuroendocrine differentiation in prostatic carcinomaHuman Pathology, 1987
- Peptide-Hormone- And Serotonin-Immunoreactive Tumour Cells in Carcinoma of the ProstatePathology - Research and Practice, 1987